SC 13G: TENAX THERAPEUTICS, INC.

AI Summary

SC 13G filing by TENAX THERAPEUTICS, INC..

Risk Assessment

Risk Level: low

FAQ

Filing Documents

• tenx13gaug24.htm (SC 13G) — 20KB
• 0001897612-24-001393.txt ( ) — 22KB

(a) Name of Issuer

Item 1(a) Name of Issuer: TENAX THERAPEUTICS INC

(b) Address of Issuer's Principal Executive Offices

Item 1(b) Address of Issuer's Principal Executive Offices: 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO, CA 94104

(a) Name of Person(s) Filing

Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates)

(b) Address of Principal Business Office

Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202

(c) Citizenship or Place of Organization

Item 2(c) Citizenship or Place of Organization: (1) Maryland

(d) Title of Class of Securities: COMMON STOCK

Item 2(d) Title of Class of Securities: COMMON STOCK

(e) Cusip Number: 88032L605

Item 2(e) Cusip Number: 88032L605

: The person filing this Schedule 13G is an

Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: The shares of Common Stock beneficially owned by the Reporting Persons reported in this Schedule 13G consist of (1) 125,000 shares of Common Stock, (2) Prefunded Warrants to acquire 2,375,000 shares of Common Stock, and (3) Warrants to acquire 1,250,000 shares of Common Stock. The Prefunded Warrants and the Warrants are each subject to a 19.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 3,408,906 shares of Common Stock outstanding as of August 10, 2024, as reported in the Form 10-Q filed by the Issuer on August 13, 2024.

: Ownership of Five Percent or Less of a Class

Item 5: Ownership of Five Percent or Less of a Class Not Applicable

: Ownership of More than Five Percent on Behalf of Another

Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client Associates. (2) [T. ROWE PRICE HEALTH SCIENCES FUND, INC. ]: T. ROWE PRICE HEALTH SCIENCES FUND, INC., of which T. ROWE PRICE ASSOCIATES, INC. is the investment adviser, holds the securities reported herein in their investment portfolio managed by T. ROWE PRICE ASSOCIATES, INC. and such funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that they hold. T. ROWE PRICE HEALTH SCIENCES FUND, INC. interest includes (1) 110,304 shares of Common Stock, (2) Prefunded Warrants to acquire 177,299 shares of Common Stock, and (3) Warrants to acquire 1,103,045 shares of Common Stock.

: Identification and Classification of the Subsidiary

Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable

: Identification and Classification of Members of the

Item 8: Identification and Classification of Members of the Group Not Applicable

: Notice of Dissolution of Group

Item 9: Notice of Dissolution of Group Not Applicable

: Certification

Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial securities referred to, which beneficial denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: September 10, 2024 Signature: /s/ Ellen York Name & Title: Ellen York, Vice President 08/31/2024

View Full Filing

View this SC 13G filing on SEC EDGAR